Novartis Digital Biomarker Innovation Challenge Questionnaire

* = required fields

Name of your company*

What kind of group owns this technology?*

Start-up company
Mature company
Academic research group

Contact person*

Contact Email Address*

Repeat Email Address*

Contact phone number*

Which country are you located?*

Name of your technology*


Which of digital biomarker research themes are you proposing an opportunity for?*

Cognition and attention
Depression and mood
Digital imaging of skin

Briefly explain what the opportunity is (i.e. which aspect of our theme/s is it connected to?)*

What physiological/behavioural parameter/s does the technology measure? Any scientific evidence/validation?

Patent (Link: )
Key scientific publication (Link: )
Other (Link: )

Device classification*

Low-risk (class I) device
Moderate-to-high risk (class II/III) device
Not applicable

Device status*

Discovery and ideation
Invention and prototyping
Clinical trial phase (Trial No.: )
Regulatory reviewing (Name of the authority: )
Product launched (Registration: )

A short presentation (up to 5 slides) supporting your description*

Why are you personally excited about this opportunity?

Apart from our specified research themes, is there anything else you would like to share with NIBR about the technology landscape in your country eg. "cutting-edge" technologies, "left-field" ideas that we should be considering in the digital biomarker/digital endpoint space?

Privacy policy

Here at ETBA, we take your privacy seriously and will only use your information to provide the services that you agree to the described business activities. The entitled Company representative and Contact person of your company have the right of access and rectify the data concerning him, her or the company by contacting us through an Email request to your corresponding contact person at ETBA or Where possible we use publicly available sources to identify alteration of your information. Meanwhile, we sincerely appreciate it if you inform us when any of the above information change. If you have further questions on data protection, please contact

Terms and conditions

Any documents and information submitted and all communication during the application process will be considered as non-confidential. Applicants agree that any documents and information submitted will be accessible to the Novartis and ETBA review committee, as well as the domain experts for the evaluation purpose. Novartis and ETBA assume no responsibility or liability for any confidential information and/or documentation submitted by applicants during the on-line application process as well as for any intellectual property rights and/or know-how contained therein.

Liability / No Right of Appeal
Novartis and ETBA assume no liability for any direct or indirect damage, including, but not limited to damage caused by loss of profit due to application of the program. Novartis and ETBA are not liable in the event of force majeure. The liability for auxiliary persons is expressly excluded in its entirety. Novartis and ETBA accepts no liability for the correctness of statements made, including statements of the review committee, experts & advisors or any other persons participating in the program. No legal rights arise from the participation in the program or the related preparation and submission of documents (e.g. no entitlement to any fees and/or expenses). The joint decision made by Novartis and ETBA is final. There is no recourse to the courts and no right of appeal.

I agree to receive future ETBA event notices.
I hereby confirm that I have read, understood and accepted the "Privacy policy" and the "Terms and conditions".

© Copyright 2017 - 2020 | Europe-Taiwan Biotech Association 歐洲台灣生技協會 | All Rights Reserved